

IDS/ #5,
JL 5/26JC872 U.S. PTO
09/973318
10/09/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Roberts et al.
 Appl. No.: To Be Assigned
 Filed: Concurrently Herewith
 For: THIOESTER POLYMER DERIVATIVES AND METHOD OF MODIFYING
 THE N-TERMINUS OF A POLYPEPTIDE THEREWITH

October 9, 2001

Box Patent Application
 Commissioner for Patents
 Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT
 CITATION UNDER 37 C.F.R. § 1.97**


Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,


 Christopher M. Humphrey
 Registration No. 43,683

Customer No. 00826
ALSTON & BIRD LLP
 Bank of America Plaza
 101 South Tryon Street, Suite 4000
 Charlotte, NC 28280-4000
 Tel Raleigh Office (919) 862-2200
 Fax Raleigh Office (919) 862-2260

<p>"Express Mail" Mailing Label Number EL 780615945 US Date of Deposit: October 9, 2001</p> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.</p> <p> Tracey S. Wright RTA 2104905v1</p>	<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on October 9, 2001.</p> <p>_____</p>
---	--

**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1 of 2

Application Number

To Be Assigned

Filing Date

Concurrently Herewith

First Named Inventor

Roberts *et al.*

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

JC872 U.S. PTO
09/973318

10/09/01

Sheet 1 of 2 Attorney Docket Number 34848/234243

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	6,184,344		Kent <i>et al.</i>	02-06-2001	Whole Document
	2	6,057,292		Cunningham <i>et al.</i>	05-02-2000	Whole Document
	3	5,985,265		Kinstler <i>et al.</i>	11-16-1999	Whole Document
	4	5,932,462		Harris <i>et al.</i>	08-03-1999	Whole Document
	5	5,824,784		Kinstler <i>et al.</i>	10-20-1998	Whole Document
	6	5,766,897		Braxton	06-16-1998	Whole Document
	7	5,252,714		Harris <i>et al.</i>	10-12-1993	Whole Document
	8	5,206,344		Katre <i>et al.</i>	04-27-1993	Whole Document
	9	4,904,584		Shaw	02-27-1990	Whole Document
	10	4,670,417		Iwasaki <i>et al.</i>	06-02-1987	Whole Document

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office ³	Kind Code Number ⁴	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	11	WO	99/67291	IMMUNEX CORPORATION	12-29-1999	Whole Document	
	12	WO	99/45026	CHIRON CORPORATION	09-10-1999	Whole Document	
	13	WO	99/24472	IMMUNOMEDICS, INC.	05-20-1999	Whole Document	
	14	WO	99/03887	BOLDER BIOTECHNOLOGY, INC.	01-28-1999	Whole Document	
	15	WO	98/35026	NOVO NORDISK A/S	08-13-1998	Whole Document	
	16	WO	96/41813	OFFORD	12-27-1996	Whole Document	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.² See attached Kinds of U.S. Patent Documents.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	To Be Assigned
<i>(Use as many sheets as necessary)</i>				Filing Date	Concurrently Herewith
Sheet	2	Of	2	First Named Inventor	Roberts et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	34848/234243

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	17	AYERS, <i>et al.</i> , "Introduction of Unnatural Amino Acids into Proteins Using Expressed Protein Ligation", <i>Biopolymers (Peptide Science)</i> , 1999, pp. 343-354, Vol. 51.	
	18	CLIPPINGDALE, <i>et al.</i> , "Peptide Thioester Preparation by Fmoc Solid Phase Peptide Synthesis for Use in Native Chemical Ligation", <i>J. Peptide Sci.</i> , 2000, pp. 225-234, Vol. 6, European Peptide Society and John Wiley & Sons, Ltd.	
	19	DAWSON, <i>et al.</i> , "Synthesis of Proteins by Native Chemical Ligation", <i>Science</i> , 1994, pp. 776-779, Vol. 266.	
	20	HACKENG, <i>et al.</i> , "Protein Synthesis by Native Chemical Ligation: Expanded Scope by Using Straightforward Methodology", <i>Proc. Natl. Acad. Sci. USA</i> , 1999, pp. 10068-10073, Vol. 96.	
	21	HANSEN, <i>et al.</i> , "Attachment of Antibodies to Sterically Stabilized Liposomes: Evaluation, Comparison and Optimization of Coupling Procedures", <i>Biochimica et Biophysica Acta</i> 1239, 1995, pp. 133-144.	
	22	HERSHFIELD <i>et al.</i> , "Use of Site-Directed Mutagenesis to Enhance the Epitope-Shielding Effect of Covalent Modification of Proteins with Polyethylene Glycol", <i>Proc. Natl. Acad. Sci. USA</i> , 1991, pp. 7185-7189, Vol. 88.	
	23	TAM, <i>et al.</i> , "Peptide Synthesis Using Unprotected Peptides Through Orthogonal Coupling Methods", <i>Proc. Natl. Acad. Sci. USA</i> , 1995, pp. 12485-12489, Vol. 92.	
	24	TAM, <i>et al.</i> , "Orthogonal Ligation Strategies for Peptide and Protein", <i>Biopolymers (Peptide Science)</i> , 1999, pp. 311-332, Vol. 51, John Wiley & Sons, Inc.	
	25	ZALIPSKY <i>et al.</i> , "Facile Synthesis of α -Hydroxy- ω -Carboxymethylpolyethylene Oxide", <i>Journal of Bioactive and Compatible Polymers</i> , 1990, pp. 227-231, Vol. 5.	
	26	ZALIPSKY, "Synthesis of an End-Group Functionalized Polyethylene Glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes", <i>Bioconjugate Chem.</i> , 1993, pp. 296-299, Vol. 4.	
	27	ZALIPSKY <i>et al.</i> , "Hydrazide Derivatives of Poly(ethylene glycol) and Their Bioconjugates", <i>American Chemical Society</i> , 1997, pp. 318-340.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. RTA 2104906v1